Suppr超能文献

载脂蛋白 B 和非高密度脂蛋白胆固醇在 2 型糖尿病且低密度脂蛋白胆固醇控制良好的个体中显示出高致动脉粥样硬化性。

Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.

机构信息

Endocrinology Department, Centro Hospitalar e Universitário do Porto, Largo Professor Abel Salazar, 4099-001, Porto, Portugal.

Endocrinology Department, Hospital de Braga, Sete Fontes, São Victor, 4710-243, Braga, Portugal.

出版信息

Lipids Health Dis. 2020 Jun 6;19(1):127. doi: 10.1186/s12944-020-01292-w.

Abstract

BACKGROUND

Lipid-lowering therapy is guided by Low-density-lipoprotein cholesterol (LDL-c) levels, although the cardiovascular disease (CVD) risk could be better reflected by other lipid parameters. This study aimed at comparing a comprehensive lipid profile between patients with type 2 diabetes mellitus (T2DM) with LDL-c concentration within and above target.

METHODS

A comprehensive lipid profile was characterized in 96 T2DM patients. The European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) 2016 and 2019 Guidelines for the Management of Dyslipidemias were used to define LDL-c targets.

RESULTS

In this population, only 28.1 and 16.7% of patients had mean LDL-c levels within target, as defined by the 2016 and 2019 guidelines, respectively. Applying the 2016 guidelines criteria, in patients with LDL-c within target, 22, 25 and 44% presented non-high-density lipoprotein cholesterol (non-HDL-c), Apolipoprotein B (ApoB) and oxidized LDL-c levels above the recommended range, respectively, whereas according to the 2019 guidelines criteria, 50, 39 and 44% of the patients with LDL-c within target had elevated high-density lipoprotein cholesterol (HDL-c), ApoB and oxidized LDL-c levels, respectively. LDL-c was strongly correlated with non-HDL-c (r = 0.850), ApoB (r = 0.656) and oxidized LDL-c (r = 0.508). Similarly, there was a strong correlation between non-HDL-c with both ApoB (r = 0.808) and oxidized LDL-c (r = 0.588).

CONCLUSIONS

These findings emphasize the limitations of only considering LDL-c concentration for cardiovascular (CV) risk assessment. Targeting only LDL-c could result in missed opportunities for CV risk reduction in T2DM patients. These data suggest that non-HDL-c, ApoB and oxidized LDL-c levels could be considered as an important part of these patients' evaluation allowing for a more accurate estimation of CV risk and hopefully better management of these high-risk patients.

摘要

背景

降脂治疗以低密度脂蛋白胆固醇(LDL-c)水平为指导,但其他脂质参数可能更好地反映心血管疾病(CVD)风险。本研究旨在比较 2 型糖尿病(T2DM)患者的综合脂质谱与 LDL-c 浓度在目标值内和目标值以上的情况。

方法

对 96 例 T2DM 患者的综合脂质谱进行了特征描述。采用欧洲心脏病学会/欧洲动脉粥样硬化学会(ESC/EAS)2016 年和 2019 年血脂异常管理指南来定义 LDL-c 目标值。

结果

在该人群中,仅分别有 28.1%和 16.7%的患者的 LDL-c 平均水平符合 2016 年和 2019 年指南定义的目标值。根据 2016 年指南标准,在 LDL-c 水平达标的患者中,分别有 22%、25%和 44%的患者非高密度脂蛋白胆固醇(non-HDL-c)、载脂蛋白 B(ApoB)和氧化型 LDL-c 水平超过推荐范围,而根据 2019 年指南标准,分别有 50%、39%和 44%的 LDL-c 水平达标的患者的高密度脂蛋白胆固醇(HDL-c)、ApoB 和氧化型 LDL-c 水平升高。LDL-c 与 non-HDL-c(r=0.850)、ApoB(r=0.656)和氧化型 LDL-c(r=0.508)均呈强相关性。同样,non-HDL-c 与 ApoB(r=0.808)和氧化型 LDL-c(r=0.588)也呈强相关性。

结论

这些发现强调了仅考虑 LDL-c 浓度评估心血管(CV)风险的局限性。仅针对 LDL-c 进行靶向治疗可能会导致 2 型糖尿病患者错失降低 CV 风险的机会。这些数据表明,non-HDL-c、ApoB 和氧化型 LDL-c 水平可作为这些患者评估的重要组成部分,从而更准确地估计 CV 风险,并有望更好地管理这些高危患者。

相似文献

2
Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity.
Sci Rep. 2019 Aug 13;9(1):11792. doi: 10.1038/s41598-019-48120-5.
7
Pitavastatin: novel effects on lipid parameters.
Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X.

引用本文的文献

1
Non-traditional lipid biomarkers in atherosclerotic cardiovascular disease: pathophysiological mechanisms and strategies to address residual risk.
Front Endocrinol (Lausanne). 2025 Jul 10;16:1576602. doi: 10.3389/fendo.2025.1576602. eCollection 2025.
5
Predictive value of ApoB/ApoA-I for recurrence within 1 year after first incident stroke.
Front Neurol. 2024 Jan 11;14:1308442. doi: 10.3389/fneur.2023.1308442. eCollection 2023.
6
Association of remnant cholesterol with CVD incidence: a general population cohort study in Southwest China.
Front Cardiovasc Med. 2023 Nov 27;10:1286286. doi: 10.3389/fcvm.2023.1286286. eCollection 2023.
8
Atherosclerosis indexes and incident T2DM in middle-aged and older adults: evidence from a cohort study.
Diabetol Metab Syndr. 2023 Feb 17;15(1):23. doi: 10.1186/s13098-023-00992-4.
10
Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy.
Animal Model Exp Med. 2022 Jun;5(3):227-238. doi: 10.1002/ame2.12249. Epub 2022 Jun 23.

本文引用的文献

1
10. Cardiovascular Disease and Risk Management: .
Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134. doi: 10.2337/dc20-S010.
3
Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity.
Sci Rep. 2019 Aug 13;9(1):11792. doi: 10.1038/s41598-019-48120-5.
5
Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults.
J Am Heart Assoc. 2019 Feb 19;8(4):e011295. doi: 10.1161/JAHA.118.011295.
6
2. Classification and Diagnosis of Diabetes: .
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. doi: 10.2337/dc19-S002.
9
Diabetes, cardiovascular disease and the microcirculation.
Cardiovasc Diabetol. 2018 Apr 18;17(1):57. doi: 10.1186/s12933-018-0703-2.
10
LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: Data from the Brisighella Heart Study cohort.
Int J Cardiol. 2018 Jun 15;261:204-208. doi: 10.1016/j.ijcard.2018.03.077. Epub 2018 Mar 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验